Indoco Remedies (INDOCO) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 performance was significantly impacted by supply-side issues in the international formulations business, mainly due to remediation activities, a US FDA warning letter at the sterile plant in Goa, and planned shutdowns at export formulation sites.

• Domestic business showed resilience, with leading brands like Cyclopam growing over 20% and outperforming the covered market in most top brands.

• Five new products were launched in the quarter, and two final ANDA approvals were received from the US FDA.

• Strategic distribution partnership established with Clarity Pharma UK, targeting 18 SKUs over 18 months.

• The company operates 11 manufacturing facilities and maintains a strong presence in both Indian and international markets.

Financial highlights

• Net revenues for Q3 FY25 were INR 3,649 million, down from INR 4,484 million year-over-year.

• EBITDA margin dropped to 5.5% (INR 201 million) from 14.6% (INR 653 million) year-over-year.

• Standalone profit for Q3 FY25 was a loss of INR 1,023 lakhs, compared to a profit of INR 2,001 lakhs in Q3 FY24.

• Consolidated profit for Q3 FY25 was a loss of INR 2,840 lakhs, compared to a profit of INR 1,556 lakhs in Q3 FY24.

• Domestic formulation revenues grew 5.5% to INR 2,242 million.

Outlook and guidance

• US business expected to remain partly impacted in Q4 due to ongoing warning letter; EU business anticipated to recover as production issues resolve.

• Remediation costs will continue for at least two more quarters, with margin recovery expected only after that period.

• No specific margin or revenue guidance provided due to ongoing uncertainties.

• Management expects domestic business to continue supporting revenue, while export business recovery depends on resolution of supply constraints.